Q-omics provides the consensus-scored NDUFS5P4 profile across patient tissues and cancer cell-line models. NDUFS5P4 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, NDUFS5P4 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, NDUFS5P4 RNA expression shows 6,239 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, BRCA, and STAD as cancer lineages where NDUFS5P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFS5P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFS5P4 survival associations across molecular data types. NDUFS5P4 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFS5P4 RNA expression–survival associations across cancer types. High NDUFS5P4 expression shows unfavorable associations in LUAD, SKCM, KIRC, PRAD and ACC, but favorable associations in HNSC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for NDUFS5P4 RNA expression.
This table summarizes NDUFS5P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for NDUFS5P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFS5P4 shows lower tumor expression in BRCA and ESCA. The BRCA box plot shows higher NDUFS5P4 RNA expression in normal versus tumor tissue (log2 FC = −0.011, t-test p = .046).
This table shows molecular features associated with NDUFS5P4 in patient tissues and cancer cell lines. In patient samples, NDUFS5P4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
